The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 6.68 — safe zoneOK
- Earnings-manipulation signal · Beneish M -2.91 — no flag raisedOK
- Earnings quality 93/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as Anika Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- OEM Channel$64.4M
- Commercial Channel$48.4M
Leadership changes
From Anika Therapeutics, Inc.'s own filings, the day they're filed.
- Anne Nunes · Chief Operations Officer · departureeff. 2025-04-25
- Michael Levitz · departureeff. 2024-06-03
- Jeffery S. Thompson · Directors · departureeff. 2024-02-24
Latest filings
- 10-Q · Quarterly report2026-04-30
- 8-K · Company announcement2026-04-29
- DEF 14A · Annual proxy (pay & governance)2026-04-28
- 10-K · Annual report2026-03-03
- 8-K · Company announcement2026-02-26
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Anika Therapeutics, Inc., every answer cited🔒
- The Intelligence Brief — added when Anika Therapeutics, Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.